Global Glucagon like Peptide 1 Market Report 2024

Glucagon-like Peptide 1 Global Market Report 2024 – By Product (Trulicity, Ozempic, Victoza, Rybelsus, Other Types), By Route of Administration (Oral, Parenteral, Other Routes), By End-Users (Hospitals, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $4000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Glucagon-like Peptide 1 Global Market Report 2023

Proud Members Of

checkslacipN checkaoirsN checkscipN

Glucagon-Like Peptide 1 Market Definition And Segments

Glucagon-like peptide 1 refers to a type of amino acid hormone of peptide that is produced in the L-cells of the intestinal epithelial endocrine. Glucagon-like peptide 1 is used to treat diseases and conditions such as diabetes and obesity respectively.

The main glucagon-like peptide 1 product types are trulicity, ozempic, victoza, rybelsus, and others. Trulicity refers to a prescription medicine that is injectable and is used to improve blood sugar. The various routes of administration are oral, parenteral, and others used in hospitals, specialty clinics, and others.

The glucagon-like peptide 1 market covered in this report is segmented –

1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types

2) By Route of Administration: Oral, Parenteral, Other Routes

3) By End-Users: Hospitals, Specialty Clinics, Other End Users

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $19.51 billion in 2023 to $21.01 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to rising prevalence of diabetes, focus on improved diabetes management, patient preference for injectable therapies, clinical efficacy and safety profiles, advancements in diabetes research.

The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $28.17 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics.

Escalating Diabetes Prevalence Drives The Global Glucagon-Like Peptide 1 Market

The rising prevalence of diabetes is expected to propel the global glucagon-like peptide 1 market going forward. Diabetes is a condition in which the blood sugar, or blood glucose, is too high. Glucagon-like peptide 1 is a medication used to treat conditions such as type 2 diabetes that may lead to weight loss and improved blood sugar. For instance, in January 2022, according to the National Library of Medicine, a US-based center of biomedical informatics and computational biology, it was estimated that global diabetes prevalence in 20-79-year-olds in 2021 was 10.5% (536.6 million people), and it is expected to increase to 12.2% (783.2 million) in 2045. Therefore, the rising prevalence of diabetes will drive glucagon-like peptide 1.

Growing Health Awareness Fuels Demand For Glucagon-Like Peptide 1 (GLP-1) Market

Increasing emphasis on personalized medicine is expected to propel the growth of the glucagon-like peptide 1 (GLP-1) market going forward. Personalized medicine refers to a type of medication that prevents, detects, or treats disease using knowledge about a person's genes or proteins. Personalized medicine allows for the tailoring of GLP-1 formulations and dosages based on individual patient needs and preferences. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based professional membership organization, in 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, which accounted for approximately 34% of all newly approved therapeutic molecular entities. Therefore, the increasing emphasis on personalized medicine is driving the growth of the glucagon-like peptide 1 (GLP-1) market.

Major companies operating in the glucagon-like peptide 1 market report are Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca PLC, Pfizer Inc., Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals PLC, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline PLC, Jiangsu Hansoh Pharmaceutical Group Co Ltd., Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd., Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc., ConjuChem Biotechnologies, Mankind Corporation, Provention Bio Inc., Regeneron Pharmaceuticals

Novo Nordisk Introduces Wegovy Therapy For Weight Management

Technological innovations are a key trend gaining popularity in the global glucagon-like peptide 1 market. Major companies operating in the glucagon-like peptide 1 market are launching new and innovative technologies to sustain their position in the market. For instance, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched Wegovy, the first and only once-weekly glucagon-like peptide 1 therapy for weight management. Wegovy completed the STEP Phase 3a clinical trial program and demonstrated a safe and well-tolerated profile across the program. This product is used by people who struggle with obesity to achieve and maintain weight loss.

Innovation In Glucagon-Like Peptide 1 Market By Novo Nordisk India

Major companies operating in the Glucagon-like Peptide 1 market are focusing on product innovations such as oral semaglutide to sustain their position in the market. Oral semaglutide refers to a medication for diabetes management that comes in pill form and is taken by mouth. For instance, in January 2022, Novo Nordisk India, an India-based healthcare company that involves clinical trials, manufacturing, and the introduction of new drugs, launched oral semaglutide, a groundbreaking peptide-in-a-pill formulation. This innovation transforms diabetes treatment, offering patients an oral alternative to injections. This enhancer serves a dual purpose by safeguarding semaglutide from degradation in the stomach, a common challenge for peptides, and by enhancing its absorption.

Eli Lilly Acquires Protomer Technologies

In July 2021, Eli Lilly and Company, a US-based pharmaceutical company, acquired Protomer Technologies for approximately $1 billion. The acquisition will provide Eli Lilly with Protomer's next-generation protein therapeutics and enable them to develop therapeutic peptides and proteins to treat people with diabetes. Protomer Technologies is a US-based biotechnology company with protein therapeutics, including glucose-responsive insulin for diabetes therapy.

North America was the largest region in the glucagon-like peptide 1 market in 2023. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glucagon-like peptide 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The glucagon-like peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The glucagon-like peptide 1 market research report is one of a series of new reports from The Business Research Company that provides glucagon-like peptide 1 market statistics, including glucagon-like peptide 1 industry global market size, regional shares, competitors with a glucagon-like peptide 1 market share, detailed glucagon-like peptide 1 market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide 1 industry. This glucagon-like peptide 1 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glucagon-like Peptide 1 Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $21.01 billion
Revenue Forecast In 2033 $28.17 billion
Growth Rate CAGR of 7.6% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Novo Nordisk AS; Sanofi SA; Eli Lilly and Co; AstraZeneca plc; Pfizer Inc; Boehringer Ingelheim International GmbH; F Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; Baxter; Hikma Pharmaceuticals plc; Zealand Pharma A/S; Intarcia Therapeutics Inc.; GlaxoSmithKline plc; Jiangsu Hansoh Pharmaceutical Group Co Ltd; Shanghai Benemae Pharmaceutical Corporation; Adocia; Biocon; Hanmi Pharmaceutical Co Ltd; Ligand Pharmaceuticals Incorporated; Advinus Therapeutics Ltd; Mitsubishi Tanabe Pharma Corporation; Daiichi Sankyo Company Limited; Sun Pharmaceutical Industries Ltd; Union Chimique Belge; Amylin Pharmaceuticals LLC; Academic Pharmaceuticals Inc; ConjuChem Biotechnologies; MannKind Corporation:; Provention Bio Inc; Regeneron Pharmaceuticals
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Glucagon-like Peptide 1 Market Characteristics

    3. Glucagon-like Peptide 1 Market Trends And Strategies

    4. Glucagon-like Peptide 1 Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Glucagon-like Peptide 1 Market Size and Growth

    5.1. Global Glucagon-like Peptide 1 Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Glucagon-like Peptide 1 Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Glucagon-like Peptide 1 Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Glucagon-like Peptide 1 Market Segmentation

    6.1. Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Trulicity

    Ozempic

    Victoza

    Rybelsus

    Other Types

    6.2. Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral

    Parenteral

    Other Routes

    6.3. Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Specialty Clinics

    Other End Users

    7. Glucagon-like Peptide 1 Market Regional And Country Analysis

    7.1. Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Glucagon-like Peptide 1 Market

    8.1. Asia-Pacific Glucagon-like Peptide 1 Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Glucagon-like Peptide 1 Market

    9.1. China Glucagon-like Peptide 1 Market Overview

    9.2. China Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Glucagon-like Peptide 1 Market

    10.1. India Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Glucagon-like Peptide 1 Market

    11.1. Japan Glucagon-like Peptide 1 Market Overview

    11.2. Japan Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Glucagon-like Peptide 1 Market

    12.1. Australia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Glucagon-like Peptide 1 Market

    13.1. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Glucagon-like Peptide 1 Market

    14.1. South Korea Glucagon-like Peptide 1 Market Overview

    14.2. South Korea Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Glucagon-like Peptide 1 Market

    15.1. Western Europe Glucagon-like Peptide 1 Market Overview

    15.2. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Glucagon-like Peptide 1 Market

    16.1. UK Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Glucagon-like Peptide 1 Market

    17.1. Germany Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Glucagon-like Peptide 1 Market

    18.5. France Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Glucagon-like Peptide 1 Market

    19.9. Italy Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Glucagon-like Peptide 1 Market

    20.13. Spain Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Glucagon-like Peptide 1 Market

    21.1. Eastern Europe Glucagon-like Peptide 1 Market Overview

    21.2. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Glucagon-like Peptide 1 Market

    22.1. Russia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Glucagon-like Peptide 1 Market

    23.1. North America Glucagon-like Peptide 1 Market Overview

    23.2. North America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Glucagon-like Peptide 1 Market

    24.1. USA Glucagon-like Peptide 1 Market Overview

    24.2. USA Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Glucagon-like Peptide 1 Market

    25.1. Canada Glucagon-like Peptide 1 Market Overview

    25.2. Canada Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Glucagon-like Peptide 1 Market

    26.1. South America Glucagon-like Peptide 1 Market Overview

    26.2. South America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Glucagon-like Peptide 1 Market

    27.1. Brazil Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Glucagon-like Peptide 1 Market

    28.1. Middle East Glucagon-like Peptide 1 Market Overview

    28.2. Middle East Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Glucagon-like Peptide 1 Market

    29.1. Africa Glucagon-like Peptide 1 Market Overview

    29.2. Africa Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Glucagon-like Peptide 1 Market Competitive Landscape And Company Profiles

    30.1. Glucagon-like Peptide 1 Market Competitive Landscape

    30.2. Glucagon-like Peptide 1 Market Company Profiles

    30.2.1. Novo Nordisk AS

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Sanofi SA

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Eli Lilly and Co

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. AstraZeneca plc

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Pfizer Inc

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Glucagon-like Peptide 1 Market Competitive Benchmarking

    32. Global Glucagon-like Peptide 1 Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Glucagon-like Peptide 1 Market

    34. Glucagon-like Peptide 1 Market Future Outlook and Potential Analysis

    34.1 Glucagon-like Peptide 1 Market In 2028 - Countries Offering Most New Opportunities

    34.2 Glucagon-like Peptide 1 Market In 2028 - Segments Offering Most New Opportunities

    34.3 Glucagon-like Peptide 1 Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Novo Nordisk AS Financial Performance
  • Table 75: Sanofi SA Financial Performance
  • Table 76: Eli Lilly and Co Financial Performance
  • Table 77: AstraZeneca plc Financial Performance
  • Table 78: Pfizer Inc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Novo Nordisk AS Financial Performance
  • Figure 75: Sanofi SA Financial Performance
  • Figure 76: Eli Lilly and Co Financial Performance
  • Figure 77: AstraZeneca plc Financial Performance
  • Figure 78: Pfizer Inc Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report